{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:11:07Z","timestamp":1788772267138,"version":"build-2803163510"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The clinical significance of increased degree of hematuria in patients affected by primary IgA Nephropathy (IgAN) remains unclear, highlighting the need for further investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From January 2018 to December 2024, a total of 696 IgAN patients with persistent hematuria were enrolled to conduct a retrospective single-center study. Patients with a follow-up-to-baseline time-averaged hematuria ratio (\u0394 u-RBC count) \u22651 were assigned to the Increased-hematuria group. The remaining patients were 1:1 matched by age, gender, baseline estimated glomerular filtration rate (eGFR), and follow-up duration to form the Decreased-hematuria group. Survival was analyzed via the Kaplan\u2013Meier (K-M) method and generalized linear mixed-effects model (GLMM), and risk factors for survival were identified using the Cox proportional hazards model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The Increased-hematuria and Decreased-hematuria groups each included 219 patients, with no significant difference in time-averaged hematuria degree between groups. Despite matched baseline demographic data and renal function, both K-M analysis (P = 0.03) and GLMM (P &amp;lt; 0.01) demonstrated that the Increased-hematuria group had significantly poorer prognosis than the Decreased-hematuria group. Increased hematuria degree was identified as an independent risk factor for reaching the composite endpoint (sustained \u2265 30% decline in eGFR from baseline or progression to end-stage renal disease [ESRD]). Notably, more substantial reduction in proteinuria levels was presented in Decreased-hematuria group but is not directly associated with prognosis among these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Increased hematuria degree is associated with adverse outcomes in patients affected by IgAN, underscoring its potential as a prognostic indicator.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/joneph\/aajag241","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:28:39Z","timestamp":1788521319000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Significance of Increased Degree of Hematuria in Patients affected by IgA Nephropathy"],"prefix":"10.1093","author":[{"given":"Ziyuan","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital of Ningbo University , Ningbo, Zhejiang, 315000 ,","place":["PR China"]},{"name":"Clinical Guidance Center for Chronic Kidney Disease Prevention and Treatment , Ningbo, Zhejiang, 315000 ,","place":["PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital of Ningbo University , Ningbo, Zhejiang, 315000 ,","place":["PR China"]},{"name":"Clinical Guidance Center for Chronic Kidney Disease Prevention and Treatment , Ningbo, Zhejiang, 315000 ,","place":["PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5405-0309","authenticated-orcid":false,"given":"Xueyan","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital of Ningbo University , Ningbo, Zhejiang, 315000 ,","place":["PR China"]},{"name":"Clinical Guidance Center for Chronic Kidney Disease Prevention and Treatment , Ningbo, Zhejiang, 315000 ,","place":["PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,7]]},"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article-pdf\/doi\/10.1093\/joneph\/aajag241\/70976002\/aajag241.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article-pdf\/doi\/10.1093\/joneph\/aajag241\/70976002\/aajag241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T08:45:10Z","timestamp":1788770710000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article\/doi\/10.1093\/joneph\/aajag241\/8786543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag241","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"aajag241"}}